RxDoctor Payments Data

Aimee Foord

Pediatric Hematology-Oncology · Las Vegas, NVNPI 1821312844

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $27,659 of the $41,072 with a category attached, or 67.3%. 30 manufacturers reported payments, led by Sanofi at 41.6% of the total. 2025 is the largest year on record at $24,165, more than ten times the $621 reported in 2022.

$41,072in general payments, 2019–2025

Across 95 payments — averaging $432.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$17K
  • Sobi, Inc$8K
  • CSL Behring$6K
  • HEMA Biologics, LLC$3K
  • Pfizer$3K
  • Novo Nordisk$2K
  • plus $2K from 24 others
$17,693in research payments, 2019–2025

Across 22 payments — averaging $804.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi US Services Inc.$14K
  • Agios Pharmaceuticals, Inc.$4K

What the payments were for

  • Consulting fees$27,65967%
  • Speaking & faculty fees$5,20013%
  • Travel & lodging$4,34211%
  • Food & beverage$3,8719%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few pediatric hematology-oncology providers in Nevadato place this figure against a meaningful peer group, so we don't.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CerezymeImiglucerase11$528,965

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SanofiCerezyme$17,073$528,96511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few pediatric hematology-oncology providers in Nevadaon file to place this against a meaningful peer group, so we don't.

Other pediatric hematology-oncology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →